Evaluation of Corneal Transparency in Eyes Treated with Brimonidine
Yıl: 2021 Cilt: 16 Sayı: 3 Sayfa Aralığı: 131 - 137 Metin Dili: İngilizce DOI: 10.37844/glauc.cat.2021.16.23 İndeks Tarihi: 24-01-2022
Evaluation of Corneal Transparency in Eyes Treated with Brimonidine
Öz: Purpose: The aim of this study was to evaluate the effects of topical 0.1% brimonidine on the corneal densitometry. Materials and Methods: This prospective study included 32 eyes of 17 patients who were diagnosed with primary open angle glaucoma and treated with 0.1% brimonidine, and 28 eyes of 14 healthy individuals. Corneal densitometry and corneal thickness (CT) were evaluated in the three corneal zones (0-2, 2-6, 6-10) by Scheimpflug corneal topography at baseline and on day 3, 17 and 30 after the treatment. Results: The CT values in the central and zones of 2, 6 and 10 mm on day 3 after treatment were statistically significantly thicker when compared to baseline and controls (p <0.001 for all). Corneal densitometry values in the central corneal layer in all three zones (0-2, 2-6, 6-10) on day 3 after treatment were statistically significantly higher when compared to baseline and controls (p <0.05 for all). However, there was no significant difference between CT and corneal densitometry values obtained at baseline and day 7 after treatment or day (p> 0.05, for all). Conclusion: Our results show that topical 0.1% brimonidine administration caused an increase in corneal thickness in all zones while an increase in corneal densitometry values in the central corneal layer in all three corneal zones at short-term. The temporary effect of brimonidine on the cornea is probably due to fluid accumulation in the central corneal layer.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Bibliyografik
- 1. Fudemberg, S.J., Batiste, C., Katz, L.J. Efficacy, safety, and current applications of brimonidine. Expert Opin. Drug Saf. 2008;7:975-9.
- 2. Reitsamer H.A., Posey M., Kiel J.W. Effects of a topical alpha2 adrenergic agonist on ciliary blood flow and aqueous production in rabbits. Exp. Eye Res. 2006;82:405-15.
- 3. Kalapesi F.B., Coroneo M.T., Hill M.A. Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection. Br. J. Ophthalmol. 2005;89:758-63.
- 4. Matthias G., Joerg M., Jens Martin R., et al. Effect of brimonidine on corneal thickness. 2011;27:503-9
- 5. Ozyol P, Ozyol E. Assessment of corneal backward light scattering in diabetic patients. Eye Contact Lens. 2018;44:92-6.
- 6. Ni Dhubhghaill S, Rozema JJ, Jongenelen S, et al. Normative values for corneal densitometry analysis by Scheimpflug optical assessment. Invest Ophthalmol Vis Sci 2014;55:162-8.
- 7. Lopes B, Ramos I, Ambrósio R Jr. Corneal densitometry in keratoconus. Cornea. 2014;33:1282-6.
- 8. Oliveira CM, Ribeiro C, Franco S. Corneal imaging with slit- scanning and Scheimpflug imaging techniques. Clin Exp Optom. 2011;94:33-42.
- 9. Becquet F, Goldschild M, Moldovan MS, et al. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res. 1998;17:419-25.
- 10. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490- 6.
- 11. Hamard P, Debbasch C, Blondin C, et al. Human trabecular cells and apoptosis: in vitro evaluation of the effect of betaxolol with or without preservative. J Fr Ophthalmol. 2002;25:777-84.
- 12. Osborne SA, Montgomery DM, Morris D, et al. Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye (Lond). 2005;19:129-37.
- 13. Manni G, Centofanti M, Sacchetti M, et al. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%- induced ocular allergy. J Glaucoma. 2004;13:163- 7.
- 14. Manabe Y, Sawada A, Mochizuki K. Corneal sterile infiltration induced by topical use of ocular hypotensive agent. European Journal of Ophthalmology. 2020;30:23-5.
- 15. Tsujinaka A, Takai Y, Inoue Y, et al. A case of bilateral deep stromal corneal opacity and vascularization after use of multiple antiglaucoma medications including brimonidine tartrate ophthalmic solution. Acta Ophthalmologica, 2019;97:948-9.
- 16. Maruyama Y, Ikeda Y, Yokoi N et al. Severe corneal disorders developed after brimonidine tartrate ophthalmic solution use. Cornea 2017;36:1567-9.
- 17. Kasuya Y, Sano I, Makino S et al. Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate. Case Rep Ophthalmol Med. 2020 May 26;2020:4803651. doi: 10.1155/2020/4803651.
- 18. Grueb M, Bartz-Schmidt K U, Rohrbach J M. Adrenergic regulation of cAMP/protein kinase A pathway in corneal epithelium and endothelium. Ophthal. Res. 2008;40:322-8.
- 19. Grueb M, Wallenfels-Thilo B, Denk O. Monoamine receptors in human corneal epithelium and endothelium. Acta Ophthalmol. Scand. 2006;84:110-5.
- 20. Cankurtaran V, Tekin K. Effects of a Single Dose of Topical Brimonidine 0.15% on Anterior Segment Morphology, Pupil Characteristics, and Choroidal Thickness in Healthy Subjects. Eye Contact Lens. 2020 May 14. doi: 10.1097/ ICL.0000000000000708. Online ahead of print.
- 21. Bonanno, J.A. Identity and regulation of ion transport mechanisms in the corneal endothelium. Prog. Retin. Eye. Res. 2003;22:69-94.
- 22. Edelhauser, H.F. The balance between corneal transparency and edema. Invest. Ophthalmol. Vis. Sci. 2006;47:1755-67.
- 23. Polat S, Ozdemir N, Soylu M, et al. Ultrastructural effects of topical beta-adrenergic antagonists and an alpha-adrenergic agonist on the rabbit cornea. Ophthalmologica 1999;213:183-8.
| APA | ALTUNEL O, gültekin irgat s, Ozcura F (2021). Evaluation of Corneal Transparency in Eyes Treated with Brimonidine. , 131 - 137. 10.37844/glauc.cat.2021.16.23 |
| Chicago | ALTUNEL ORHAN,gültekin irgat saadet,Ozcura Fatih Evaluation of Corneal Transparency in Eyes Treated with Brimonidine. (2021): 131 - 137. 10.37844/glauc.cat.2021.16.23 |
| MLA | ALTUNEL ORHAN,gültekin irgat saadet,Ozcura Fatih Evaluation of Corneal Transparency in Eyes Treated with Brimonidine. , 2021, ss.131 - 137. 10.37844/glauc.cat.2021.16.23 |
| AMA | ALTUNEL O,gültekin irgat s,Ozcura F Evaluation of Corneal Transparency in Eyes Treated with Brimonidine. . 2021; 131 - 137. 10.37844/glauc.cat.2021.16.23 |
| Vancouver | ALTUNEL O,gültekin irgat s,Ozcura F Evaluation of Corneal Transparency in Eyes Treated with Brimonidine. . 2021; 131 - 137. 10.37844/glauc.cat.2021.16.23 |
| IEEE | ALTUNEL O,gültekin irgat s,Ozcura F "Evaluation of Corneal Transparency in Eyes Treated with Brimonidine." , ss.131 - 137, 2021. 10.37844/glauc.cat.2021.16.23 |
| ISNAD | ALTUNEL, ORHAN vd. "Evaluation of Corneal Transparency in Eyes Treated with Brimonidine". (2021), 131-137. https://doi.org/10.37844/glauc.cat.2021.16.23 |
| APA | ALTUNEL O, gültekin irgat s, Ozcura F (2021). Evaluation of Corneal Transparency in Eyes Treated with Brimonidine. Glokom Katarakt, 16(3), 131 - 137. 10.37844/glauc.cat.2021.16.23 |
| Chicago | ALTUNEL ORHAN,gültekin irgat saadet,Ozcura Fatih Evaluation of Corneal Transparency in Eyes Treated with Brimonidine. Glokom Katarakt 16, no.3 (2021): 131 - 137. 10.37844/glauc.cat.2021.16.23 |
| MLA | ALTUNEL ORHAN,gültekin irgat saadet,Ozcura Fatih Evaluation of Corneal Transparency in Eyes Treated with Brimonidine. Glokom Katarakt, vol.16, no.3, 2021, ss.131 - 137. 10.37844/glauc.cat.2021.16.23 |
| AMA | ALTUNEL O,gültekin irgat s,Ozcura F Evaluation of Corneal Transparency in Eyes Treated with Brimonidine. Glokom Katarakt. 2021; 16(3): 131 - 137. 10.37844/glauc.cat.2021.16.23 |
| Vancouver | ALTUNEL O,gültekin irgat s,Ozcura F Evaluation of Corneal Transparency in Eyes Treated with Brimonidine. Glokom Katarakt. 2021; 16(3): 131 - 137. 10.37844/glauc.cat.2021.16.23 |
| IEEE | ALTUNEL O,gültekin irgat s,Ozcura F "Evaluation of Corneal Transparency in Eyes Treated with Brimonidine." Glokom Katarakt, 16, ss.131 - 137, 2021. 10.37844/glauc.cat.2021.16.23 |
| ISNAD | ALTUNEL, ORHAN vd. "Evaluation of Corneal Transparency in Eyes Treated with Brimonidine". Glokom Katarakt 16/3 (2021), 131-137. https://doi.org/10.37844/glauc.cat.2021.16.23 |
